Q-omics provides the consensus-scored BTF3P11 profile across patient tissues and cancer cell-line models. BTF3P11 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BTF3P11 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, BTF3P11 protein abundance shows 7,034 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, LUAD, and GBM as cancer lineages where BTF3P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3P11 survival associations across molecular data types. BTF3P11 RNA expression shows survival associations in the most cancer types (11), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3P11 RNA expression–survival associations across cancer types. High BTF3P11 expression shows unfavorable associations in KIRP, OV, COAD, STAD, LIHC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for BTF3P11 RNA expression.
This table summarizes BTF3P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3P11 shows lower tumor expression in STAD and higher tumor expression in LUAD and KIRC. The LUAD box plot shows higher BTF3P11 RNA expression in tumor versus normal tissue (log2 FC = +0.130, t-test p < 0.001).
This table shows molecular features associated with BTF3P11 in patient tissues and cancer cell lines. In patient samples, BTF3P11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BTF3P11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and NCI60_ALL.
